Hematopoiesis, the lifelong process of blood cell formation, is exquisitely regulated by a complex interplay of cellular signals and molecular pathways. Disruption in this delicate equilibrium often culminates in hematological malignancies such as AML, a fast-progressing cancer characterized by the accumulation of immature myeloid cells. Despite advances in chemotherapy and targeted therapies, relapse rates and treatment resistance remain high, necessitating the identification of novel molecular targets that can modulate disease progression more effectively.

Succinate, a key intermediate of the tricarboxylic acid (TCA) cycle, has recently gained attention beyond its metabolic function for its extracellular signaling capacity through SUCNR1, also known as GPR91. This G protein-coupled receptor mediates various physiological responses, including blood pressure regulation and immune cell activation. Cuminetti, Boet, Heugel, and colleagues have now revealed that SUCNR1 is a critical checkpoint in hematopoietic stem and progenitor cell (HSPC) regulation, with profound implications for AML biology.

Through an elegant series of in vivo and in vitro experiments, the research team demonstrated that SUCNR1 activation imposes a restrictive effect on HSPC expansion. They found that succinate accumulation, often a hallmark of metabolic dysregulation in the bone marrow niche, signals through SUCNR1 to maintain hematopoietic homeostasis by enforcing quiescence on progenitor populations. This mechanism effectively prevents excessive proliferation that can predispose cells to malignant transformation.

Moreover, the study uncovered that the lack or inhibition of SUCNR1 disrupts this metabolic checkpoint, leading to aberrant hematopoietic proliferation and an accelerated progression of AML. Using genetically engineered mouse models deficient in SUCNR1, the researchers observed a striking increase in leukemic burden, alongside dysregulated hematopoiesis, culminating in worsened survival outcomes. This provided compelling evidence that SUCNR1 acts as a natural tumor suppressor within the hematopoietic system.

At the cellular signaling level, SUCNR1 engagement modulates downstream pathways involved in cell cycle regulation, apoptosis, and differentiation. The researchers highlighted its role in modulating the AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathways, which are crucial for cellular energy sensing and proliferation control. Succinate binding to SUCNR1 triggered a signaling cascade that culminated in the activation of these metabolic checkpoints, thereby ensuring cellular integrity.

Interestingly, the study also showed that leukemic blasts themselves alter succinate levels in the bone marrow microenvironment, suggesting a feedback loop where tumor metabolism influences disease progression. This crosstalk between cancer metabolism and signaling receptors emphasizes the dynamic interplay that drives AML pathogenesis and resistance to therapy.

The therapeutic implications are profound. By targeting SUCNR1 or modulating its signaling axis, it might be possible to restore controlled hematopoiesis and inhibit leukemic expansion. The authors propose that pharmacological agents enhancing SUCNR1 activity could serve as adjuncts to existing chemotherapies, potentially reducing relapse rates and improving patient outcomes. Conversely, metabolic interventions that alter succinate levels might also recalibrate SUCNR1-mediated signaling.

Importantly, the research dispels prior ambiguity around the role of succinate in cancer, challenging the simplistic view of succinate solely as an oncometabolite. Instead, it positions succinate as a nuanced metabolic messenger with context-dependent roles, underscoring the complexity of metabolic regulation in cancer biology.

This work also opens avenues for biomarker development. Measuring succinate levels or SUCNR1 expression in patients with AML could aid in disease stratification and monitoring therapeutic responses. Given the receptor’s accessibility as a G protein-coupled receptor, it is an attractive candidate for drug development, as many existing pharmaceuticals target this receptor family.

Furthermore, the study offers insights into the broader implications of metabolic signaling in stem cell biology and malignancies. It suggests that similar metabolic checkpoints may exist in other stem cell compartments, highlighting metabolism as a universal yet finely tuned regulator of stemness and differentiation.

By combining advanced genetic models, metabolomic profiling, and mechanistic biochemistry, Cuminetti and colleagues provide a comprehensive blueprint of how SUCNR1 orchestrates hematopoiesis and suppresses leukemia. Their multidisciplinary approach underscores the importance of integrating metabolism and signaling in cancer research.

As AML continues to pose significant clinical challenges, this research injects fresh optimism into the field. The identification of SUCNR1 as a gatekeeper in hematopoiesis not only enriches fundamental biology but also translates directly into new therapeutic strategies that could transform patient care.

In conclusion, the discovery of SUCNR1’s role in restricting hematopoietic proliferation and preventing AML progression embodies a paradigm shift. It bridges metabolism, receptor signaling, and cancer biology in an unprecedented manner. Future studies will undoubtedly explore the therapeutic potential of this receptor, potentially heralding a new class of metabolic-based therapies that reshape the treatment landscape for AML and beyond.

Subject of Research: Succinate receptor 1 (SUCNR1) in hematopoiesis regulation and acute myeloid leukemia progression

Article Title: Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression

Article References:
Cuminetti, V., Boet, E., Heugel, M. et al. Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68906-2

Image Credits: AI Generated

At the heart of this emergent concept lies the chemokine receptor CXCR4, a G protein-coupled receptor widely expressed on hematopoietic stem cells and implicated in cell homing and retention within the bone marrow. In acute leukemia, leukemic blasts exploit CXCR4-mediated signaling to anchor themselves within protective microenvironments, enabling evasion from chemotherapy-induced cytotoxicity. This receptor’s pivotal role in leukemic cell trafficking and survival has positioned it as an attractive therapeutic target, but the translation from bench to bedside has faced numerous challenges, not least the capacity to both detect and effectively eradicate CXCR4-positive malignancies.

Pentixafor and pentixather represent a cutting-edge class of molecules designed for CXCR4-targeted theranostics—a fusion of therapy and diagnostics that promises precision oncology tailored to the molecular landscape of individual patients. Pentixafor, a radiolabeled peptide, binds specifically to CXCR4, enabling high-resolution positron emission tomography (PET) imaging of CXCR4 expression in vivo. This noninvasive visualization allows clinicians to map leukemic infiltration with unparalleled accuracy, stratify patients for targeted therapy, and monitor therapeutic response dynamically. Complementary to pentixafor, pentixather is a therapeutic analogue conjugated with cytotoxic radionuclides capable of delivering lethal doses of radiation directly to leukemia cells expressing CXCR4, thereby minimizing collateral damage to normal tissues.

The convergence of imaging and targeted radiotherapy in this theranostic duo addresses a long-standing unmet need in acute leukemia treatment: the eradication of minimal residual disease (MRD) within sanctuary sites such as the bone marrow microenvironment. These niches shelter leukemic stem cells that are innately resistant to conventional chemotherapy, often precipitating relapse. By leveraging the high affinity of pentixafor and pentixather for CXCR4, clinicians can not only visualize these elusive cell populations but also deliver focused radiotherapeutic agents to annihilate them. This targeted approach is poised to significantly improve patient outcomes by overcoming intrinsic and acquired drug resistance mechanisms.

From a biochemical perspective, the interaction of pentixafor and pentixather with CXCR4 involves precise molecular recognition within the receptor’s binding pocket, allowing selective targeting of leukemia cells. Structural modifications of these molecules have optimized their pharmacokinetics and stability, enhancing tumor-to-background ratios in imaging and maximizing delivery of therapeutic radionuclides. The radiolabeling process, employing isotopes such as Gallium-68 for pentixafor PET imaging and Lutetium-177 or Yttrium-90 for pentixather therapy, has been refined to ensure high specific activity and safety, representing a marvel of modern radiopharmaceutical chemistry.

Clinical studies conducted to date have demonstrated promising results, with patients exhibiting significant reductions in leukemic burden and manageable toxicity profiles following CXCR4-directed radioligand therapy. The integration of this approach into existing treatment protocols may enable dose reduction of systemic chemotherapy and radiation, thereby sparing patients from debilitating side effects. Moreover, the ability to personalize treatment based on PET imaging of CXCR4 expression presents an exciting avenue for precision medicine, potentially transforming the therapeutic landscape of acute leukemia from a generic to a highly individualized discipline.

Importantly, the implications of this research extend beyond acute leukemia. CXCR4 overexpression is a hallmark of multiple hematological malignancies and certain solid tumors as well, suggesting that pentixafor and pentixather theranostics could be adapted for broader oncology applications. The concept of exploiting the tumor microenvironment and its receptor-mediated interactions through personalized radioligand therapy aligns with contemporary efforts to develop smart therapies that circumvent the limitations of traditional chemotherapy and immunotherapy.

However, challenges remain before widespread clinical implementation can be realized. These include optimizing dosimetry to maximize therapeutic effect while minimizing off-target toxicity, understanding long-term outcomes and potential late effects of radionuclide therapy, and integrating this approach with emerging modalities such as CAR-T cell therapy and immune checkpoint inhibitors. Regulatory approvals and cost considerations must also be navigated vigilantly to ensure equitable patient access.

The insight gained from this CXCR4-targeted theranostic strategy highlights the importance of multidisciplinary collaboration, spanning molecular biology, nuclear medicine, hematology, and pharmacology. It underscores a broader paradigm shift in oncology, moving away from one-size-fits-all therapies toward bespoke regimens informed by molecular imaging and radionuclide therapy. Such advances fulfill the promise of smart medicine—offering treatments that are simultaneously precise, efficacious, and less burdensome to patients.

As research progresses, novel agents with improved selectivity and therapeutic indices are anticipated, alongside combinatorial regimens integrating CXCR4 theranostics with other targeted treatments, immunomodulators, or epigenetic therapies. Animal models and clinical trials will continue to refine therapeutic windows and elucidate mechanisms of resistance, fostering continuous innovation.

Ultimately, the marriage of molecular targeting and radiotheranostics in acute leukemia through pentixafor and pentixather marks a watershed moment. It exemplifies how decoding the biological crosstalk between cancer cells and their microenvironment can unlock new vulnerabilities, transform diagnostics, and inaugurate a new era of precision oncology. For patients battling acute leukemia, this heralds a future where disease control is not just a hope but an attainable reality.

Subject of Research: CXCR4-targeted theranostics in acute leukemia, focusing on disrupting leukemic cell interactions with the bone marrow microenvironment using pentixafor and pentixather.

Article Title: CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.

Article References:
Rahimian, S., Najafi, H. & Doroudian, M. CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather. Med Oncol 42, 402 (2025). https://doi.org/10.1007/s12032-025-02924-w

Image Credits: AI Generated